Gregory Adams work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
Gregory Adams personal email
- Valid
Gregory Adams phone numbers
Immunologist with over 30 years experience in developing antibody-based agents for the treatment and detection of cancer. Chief Scientific Officer at Elucida Oncology. Elucida is a preclinical stage oncology company developing targeted ultra-small nanodrug conjugates based upon the C'Dot platform.Formerly Chief Scientific Officer at Sesen Bio/Eleven Bio and Chief Development Officer at Eleven/Viventia Bio, Director of Biological Research and Therapeutics at Fox Chase Cancer Center (FCCC) and Co-leader of the Developmental Therapeutics Program at FCCCCo-founder and former acting CEO of RAbD Biotech LLC, a start up company that used in silico design methods to design biotherapeutics.Previously headed a lab at FCCC focused on engineering/evaluating antibodies and antibody-drug conjugates for the treatment of cancer and on developing antibody-based biosensors. Merrimack Pharmaceutical's anti-HER2/HER3 bispecific antibody MM-111, which made it to phase 2 trials, was developed by my group in collaboration with Jim Marks (UCSF) and licensed to Merrimack.I serve on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals and rotated off the editorial board of Cancer Research. I was a member of the Integration Panel of the Department of Defense's Breast Cancer Research Program and served as a reviewer for other panels including the NCI and the ACS and am a member of the Antibody Society's Board of Directors. Prior to joining Viventia Bio I was an adviser to biotech companies such as Endo Pharmaceuticals, Mersana, Symphogen, Avipep, AvidBiologics. I was as an expert witness for Centocor/J&J in a patent infringement lawsuit against Abbott (Remicade vs. Humira).
-
ConsultantGreg Adams ConsultingPhiladelphia, Pa, Us -
Scientific Advisory Board MemberIntegral Molecular Jun 2015 - PresentPhiladelphia, Pennsylvania, Us -
Chief Scientific OfficerElucida Oncology, Inc. Aug 2019 - Jun 2024Monmouth Junction, Nj, UsElucida Oncology was a clinical stage company developing targeted ultra-small C'-dot (nanoparticle) Drug Conjugates (CDCs) for the treatment of cancer. CDCs built upon the successes of antibody drug conjugate (ADC) technology and addressed the limitations of ADCs by delivering payloads deep into tumors and accessing tumors in difficult to target locations like the brain. -
Chief Scientific OfficerSesen Bio Jan 2017 - Mar 2019Note: Eleven Bio changed its name to Sesen Bio in May of 2018. As CSO I focused on guiding the development of the product line of sesen bio (Eleven Bio) which is primarily focused on antibody-based fusion proteins containing potent toxins capable of killing dividing and non-dividing cancer cells. My role included identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I was also part of the team working on securing additional financial investment into Eleven Biotherapeutics, presenting the company to bankers, analysts and investment groups as the need arises.
-
Chief Development OfficerSesen Bio Sep 2016 - Jan 2017Following the acquisition of Viventia by Eleven Biotherapeutics I joined the management team of Eleven as the Chief Development Officer. My position was focused on guiding the development of the product line including identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I was part of the team working on Securing additional financial investment into Eleven Biotherapeutics, presenting the company to bankers, analysts and investment groups.
-
Chief Development OfficerViventia Bio Inc. May 2015 - Sep 2016CaI joined Viventia Bio as their Chief Development Officer in May of 2015. My evolving position is focused on guiding the development of the product line including identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I am also part of the team working on Viventia's IPO and presenting the company to bankers, analysts and in testing the waters meetings with investment groups. -
Member: Scientific Advisory BoardViventia Bio Inc. 2001 - May 2015Ca
-
Adjunct Associate ProfessorFox Chase Cancer Center May 2015 - May 2016Philadelphia, Pa, UsAdjunct Assoc. Professor in the Molecular Therapeutics Program at Fox Chase Cancer Center. -
Director Of Biological Research And TherapeuticsFox Chase Cancer Center Dec 2013 - May 2015Philadelphia, Pa, UsThis position evolved from my prior role as a founder and Co-leader of the Developmental Therapeutics Program at the Fox Chase Cancer Center. One of my key goals in this position is to foster collaborations between Fox Chase Physicians and Scientists and their counterparts in pharma, biotech and other academic institutions that lead to the development of new biologic agents for the detection and treatment of cancer.
-
Associate ProfessorFox Chase Cancer Center Jun 2008 - May 2015Philadelphia, Pa, UsTenured member of the faculty of the Developmental Therapeutics Program
-
Tenured Faculty MemberFox Chase Cancer Center 2008 - May 2015Philadelphia, Pa, UsLead a research group focused on developing antibody-based agents for the treatment of cancer.
-
Co-Leader - Developmental Therapeutics ProgramFox Chase Cancer Center Jan 2009 - Dec 2013Philadelphia, Pa, UsCo-leader of one of the five academic research programs (Departments) at Fox Chase Cancer Center in Philadelphia. The Developmental Therapeutics Program is a collaborative effort between basic science researchers and cancer physicians with expertise in clinical trials. We seek to understand the fundamental molecular events that drive cancer and exploit this knowledge in the development of novel therapeutics.
-
Associate MemberFox Chase Cancer Center 2001 - 2008Philadelphia, Pa, Us
-
Assistant MemberFox Chase Cancer Center Jun 1994 - 2001Philadelphia, Pa, Us
-
Adjunct Associate ProfessorTemple University School Of Medicine Mar 2008 - 2016Philadelphia, Pennsylvania, Us -
Scientific Advisory Board MemberSevion Therapeutics May 2014 - May 2015
-
Ceo And Co-FounderRabd Biotech Jan 2014 - May 2015Hatboro, Pa, UsCo-founder of RAbD Biotech LLC, a start up focused on rationally developing biotherapeutics including hormones and antibodies using knowledge of the 3D structure and sequence of the desired therapeutic target. We are using knowledge of protein structure and in silico design methods to design and produce agents that specifically bind to functional sites on receptors or other functional targets. Our primary focus is highly conserved sequences that are difficult to target using currently available methods.Our lead agent is RAD-003, a first-in-class biologic agent for the treatment of ovarian cancer. -
Scientific Advisory Board MemberMersana Therapeutics Jan 2013 - May 2015Cambridge, Ma, Us -
Scientific Advisory Board MemberSymphogen Oct 2011 - May 2015Ballerup, DkActive member of the Symphogen SAB -
Chief Scientific AdvisorAvid Biologics (Renamed Formation Biologics) Jan 2011 - May 2015
-
Member: Scientific Advisory BoardAvipep 2008 - May 2015
-
Oncology Advisory Board MemberEndo Pharmaceuticals May 2010 - Jun 2014Malvern, Pa, Us -
ConsultantTeva Pharmaceuticals May 2014 - May 2014Tel-Aviv, IlHigh-level consultation for Teva Pharmaceuticals on an in licensing / acquisition opportunity. -
Scientific Advisory Board MemberYm Biosciences Jun 2010 - Mar 2013Member of YM's SAB until it was acquired by Gilead Sciences, Inc.
-
Member: Scientific Advisory BoardSolixia 2008 - 2011
-
Expert WitnessWoodcock Washburn Llp Oct 2008 - Jul 2009Philadelphia, Pa, UsServed as an expert witness on behalf of Centocor in the Remicade vs Humira patent infringement lawsuit filed against Abbott Pharmaceuticals. Prepared and reviewed expert opinions on infringement, enablement, written description and testified in the jury trial in Marshall Texas.
Gregory Adams Skills
Gregory Adams Education Details
-
University Of California, DavisImmunology -
University Of California, Santa CruzBiology
Frequently Asked Questions about Gregory Adams
What company does Gregory Adams work for?
Gregory Adams works for Greg Adams Consulting
What is Gregory Adams's role at the current company?
Gregory Adams's current role is Consultant.
What is Gregory Adams's email address?
Gregory Adams's email address is gr****@****bio.com
What is Gregory Adams's direct phone number?
Gregory Adams's direct phone number is (888) 369*****
What schools did Gregory Adams attend?
Gregory Adams attended University Of California, Davis, University Of California, Santa Cruz.
What skills is Gregory Adams known for?
Gregory Adams has skills like Cancer, Immunology, Biotechnology, Oncology, Cancer Research, Life Sciences, Molecular Biology, Antibodies, Drug Discovery, Clinical Trials, Biochemistry, Clinical Development.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial